This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than ...

Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (SKYE) (“Skye”), a ...

Skye Bioscience (NASDAQ:SKYE) is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space. The massive success of glucagon-like peptide-1 (GLP-1) ...

SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat ...

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

SKYE BIOSCIENCE ($SKYE) is expected to release its quarterly earnings data on Wednesday, March 19th after market close, per Finnhub. Analysts are expecting revenue of ...

Skye Bioscience (NASDAQ:SKYE) is set to give its latest quarterly earnings report on Tuesday, 2026-03-10. Here's what investors need to know before the announcement. Analysts estimate that Skye ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the ...

Skye Bioscience, Inc. ( (SKYE)) has released its Q3 earnings. Here is a breakdown of the information Skye Bioscience, Inc. presented to its investors. Skye Bioscience, Inc. is a clinical-stage ...

SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic ...

NEW YORK CITY, NY / ACCESS Newswire / December 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE) and ...

SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other ...